<\/p>\n
Results reinforce commitment to next-generation oral SERD development program<\/p>\n
WILMINGTON, Del., October 26, 2022–(BUSINESS WIRE)–Positive high-level results from the SERENA-2 Phase II trial showed that AstraZeneca\u2019s next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant met the primary endpoint of demonstrating a statistically significant and clinically meaningful progression-free survival (PFS) benefit at both 75mg and 150mg dose levels versus FASLODEX\u00ae (fulvestrant) 500mg in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer, previously treated with endocrine therapy for advanced disease.<\/p>\n
Camizestrant was well tolerated, and its safety profile was consistent with that observed in previous trials with no new safety signals identified.<\/p>\n
Breast cancer is the most common cancer worldwide, with an estimated 2.3 million patients diagnosed in 2020.1 Approximately 70% of breast cancer tumors are considered HR-positive and HER2-low or negative.2 Endocrine therapies are widely used for the treatment of HR-positive breast cancer, but many patients with advanced disease develop resistance to 1st-line CDK4\/6 inhibitors and estrogen receptor-targeting therapies, underscoring the need for additional options.3<\/p>\n
Mafalda Oliveira, MD, PhD, Vall d\u2018Hebron Institute of Oncology in Barcelona, Spain and lead investigator in the SERENA-2 Phase II trial, said: “The results from SERENA-2 show that camizestrant provides a significant improvement in progression-free survival compared to FASLODEX, which has been used to treat patients with HR-positive breast cancer for almost twenty years. These results are meaningful, highlighting the potential of this next-generation oral SERD and supporting the ongoing research program.”<\/p>\n
Susan Galbraith, EVP, Oncology R&D, AstraZeneca, said: “Our goal with our next generation oral SERD camizestrant is to improve on currently available endocrine therapies for patients with HR-positive breast cancer in early and metastatic disease. The exciting efficacy and compelling safety results from the SERENA-2 trial underscore the potential for camizestrant to achieve this goal in patients with ER-driven breast cancer and we look forward to advancing our comprehensive Phase III clinical program for camizestrant.”<\/p>\n
Story continues<\/p>\n
The data will be presented at a forthcoming medical meeting.<\/p>\n
AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer, including the pivotal SERENA-6 Phase III trial assessing camizestrant in combination with cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitors (palbociclib or abemaciclib) in patients with HR-positive metastatic breast cancer who have detectable ESR1 mutations on 1st-line treatment and the SERENA-4 Phase III trial evaluating camizestrant plus palbociclib in HR-positive, locally advanced or metastatic breast cancer from the start of therapy in the 1st-line setting. The indication for SERENA-6 has been granted Fast Track Designation by the US Food and Drug Administration.<\/p>\n
AstraZeneca has a comprehensive portfolio of approved and potential new medicines in development for patients with breast cancer. In addition to these results, the Company has also announced today positive results from the CAPitello-291 Phase III trial of capivasertib in HR-positive advanced breast cancer.<\/p>\n
Important Safety Information About FASLODEX\u00ae (fulvestrant) injection<\/p>\n
Contraindications<\/p>\n
FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema, have been reported in association with FASLODEX<\/p>\n<\/li>\n<\/ul>\n
Warnings and Precautions<\/p>\n
Risk of Bleeding<\/p>\n
Because FASLODEX is administered intramuscularly, it should be used with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use<\/p>\n<\/li>\n<\/ul>\n
Hepatic Impairment<\/p>\n
Injection Site Reaction<\/p>\n
Use caution while administering FASLODEX at the dorsogluteal injection site due to the proximity of the underlying sciatic nerve. Injection site-related events, including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy, have been reported with FASLODEX injection<\/p>\n<\/li>\n<\/ul>\n
Embryo-Fetal Toxicity and Lactation<\/p>\n
Pregnancy testing is recommended for females of reproductive potential within seven days prior to initiating FASLODEX<\/p>\n<\/li>\n
Advise pregnant women of the potential risk to a fetus. Advise women of reproductive potential to use effective contraception during FASLODEX treatment and for 1 year after the last dose. Advise lactating women not to breastfeed during treatment with FASLODEX and for 1 year after the final dose because of the potential risk to the infant<\/p>\n<\/li>\n<\/ul>\n
Immunoassay Measurement of Serum Estradiol<\/p>\n
Due to structural similarity of fulvestrant and estradiol, FASLODEX can interfere with estradiol measurement by immunoassay, resulting in falsely elevated estradiol levels<\/p>\n<\/li>\n<\/ul>\n
Adverse Reactions<\/p>\n
Monotherapy<\/p>\n
The most common adverse reactions occurring in \u22655% of patients receiving FASLODEX 500 mg were injection site pain, nausea, bone pain, arthralgia, headache, back pain, fatigue, pain in extremity, hot flash, myalgia, vomiting, anorexia, diarrhea, asthenia, musculoskeletal pain, cough, dyspnea, and constipation<\/p>\n<\/li>\n
Increased hepatic enzymes (ALT, AST, ALP) occurred in >15% of FASLODEX patients and were not dose-dependent<\/p>\n<\/li>\n<\/ul>\n
Combination Therapy \u2013 FASLODEX plus ribociclib<\/p>\n
The most frequently reported (\u22655%) Grade 3 or 4 adverse reactions in patients receiving FASLODEX plus ribociclib in descending frequency were neutropenia, leukopenia, infections, and abnormal liver function tests<\/p>\n<\/li>\n
The most common adverse reactions (\u226520%) of any grade reported in patients receiving FASLODEX 500 mg plus ribociclib 600 mg\/day were neutropenia, infections, leukopenia, cough, nausea, diarrhea, vomiting, constipation, pruritus, and rash<\/p>\n<\/li>\n
Additional adverse reactions in patients receiving FASLODEX plus ribociclib included asthenia, dyspepsia, thrombocytopenia, dry skin, dysgeusia, electrocardiogram QT prolonged, dry mouth, vertigo, dry eye, lacrimation increased, erythema, hypocalcemia, blood bilirubin increased, and syncope<\/p>\n<\/li>\n<\/ul>\n
Combination Therapy\u2014FASLODEX plus palbociclib<\/p>\n
The most frequently reported Grade \u22653 adverse reactions in patients receiving FASLODEX plus palbociclib in descending frequency were neutropenia and leukopenia<\/p>\n<\/li>\n
Adverse reactions (\u226510%) of any grade reported in patients receiving FASLODEX 500 mg plus palbociclib 125 mg\/day by descending frequency were neutropenia, leukopenia, infections, fatigue, nausea, anemia, stomatitis, diarrhea, thrombocytopenia, vomiting, alopecia, rash, decreased appetite, and pyrexia<\/p>\n<\/li>\n
Additional adverse reactions occurring at an overall incidence of <10% of patients receiving FASLODEX plus palbociclib included asthenia, aspartate aminotransferase increased, dysgeusia, epistaxis, lacrimation increased, dry skin, alanine aminotransferase increased, vision blurred, dry eye, and febrile neutropenia<\/p>\n<\/li>\n<\/ul>\n
Combination Therapy\u2014FASLODEX plus abemaciclib<\/p>\n
The most frequently reported (\u22655%) Grade 3 or 4 adverse reactions in patients receiving FASLODEX plus abemaciclib were neutropenia, diarrhea, leukopenia, anemia, and infections<\/p>\n<\/li>\n
The most common adverse reactions (\u226520%) of any grade reported in patients receiving FASLODEX 500 mg plus abemaciclib 150 mg twice daily were diarrhea, fatigue, neutropenia, nausea, infections, abdominal pain, anemia, leukopenia, decreased appetite, vomiting, and headache<\/p>\n<\/li>\n<\/ul>\n
Indications for FASLODEX<\/p>\n
Monotherapy<\/p>\n
FASLODEX is an estrogen receptor antagonist indicated for the treatment of:<\/p>\n
Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy<\/p>\n<\/li>\n
HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy<\/p>\n<\/li>\n<\/ul>\n
Combination Therapy<\/p>\n
FASLODEX is indicated for the treatment of:<\/p>\n
HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine-based therapy or following disease progression on endocrine therapy<\/p>\n<\/li>\n
HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy<\/p>\n<\/li>\n<\/ul>\n
Please see full Prescribing Information for FASLODEX with Patient Information.<\/p>\n
Notes<\/p>\n
HR-positive breast cancer<\/p>\n
HR-positive breast cancer (expressing estrogen or progesterone receptors, or both), is the most common subtype of breast cancer, and the growth of HR-positive breast cancer cells is often driven by ER.2,4,5 Endocrine therapies that target ER-driven disease are widely used as 1st-line treatment for this form of breast cancer in the advanced setting, and often paired with CDK4\/6 inhibitors.3 However, resistance to CDK4\/6 inhibitors and current endocrine therapies develops in many patients with advanced disease and treatment options are limited.3 Optimizing endocrine therapy and overcoming resistance for patients with ER-driven disease at all stages of treatment are active areas of focus for breast cancer research.<\/p>\n
SERENA-2<\/p>\n
SERENA-2 is a randomized, open-label, parallel group, multicenter Phase II trial evaluating camizestrant at several dose levels compared to FASLODEX in advanced ER-positive, HER2-negative breast cancer. The primary endpoints are PFS defined by response evaluation criteria in solid tumors (RECIST) version 1.1 for 75mg camizestrant versus FASLODEX (500mg) and for 150mg camizestrant versus FASLODEX. 240 patients were randomized to receive camizestrant or FASLODEX until disease progression. Secondary endpoints include safety, objective response rate and clinical benefit rate (CBR) at 24 weeks.<\/p>\n
SERENA-2 is part of a larger clinical program focused on camizestrant, evaluating the safety and efficacy when used as a monotherapy or in combination with other agents, to address a number of areas of unmet need in HR-positive breast cancer.<\/p>\n
Camizestrant<\/p>\n
Camizestrant is a potent, next-generation oral SERD and pure ER\u03b1 antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.<\/p>\n
The SERENA-1 Phase I trial demonstrated that camizestrant is well tolerated and has a promising anti-tumor profile when administered alone or in combination with palbociclib, a CDK4\/6 inhibitor. Combinations with other agents are ongoing in SERENA-1.<\/p>\n
AstraZeneca in breast cancer<\/p>\n
Driven by a growing understanding of breast cancer biology, AstraZeneca is starting to challenge, and redefine, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need \u2013 with the bold ambition to one day eliminate breast cancer as a cause of death.<\/p>\n
AstraZeneca has a comprehensive portfolio of approved and promising compounds in development that leverage different mechanisms of action to address the biologically diverse breast cancer tumor environment.<\/p>\n
With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca is aiming to improve outcomes in previously treated HER2-positive and HER2-low breast cancer. AstraZeneca and Daiichi Sankyo are exploring its potential in earlier lines of treatment and in new breast cancer settings.<\/p>\n
In HR-positive breast cancer, AstraZeneca continues to improve outcomes with foundational medicines FASLODEX and goserelin and aims to reshape the HR-positive space with ngSERD and potential new medicine camizestrant as well as a potential first-in-class AKT kinase inhibitor, capivasertib. AstraZeneca is also collaborating with Daiichi Sankyo to explore the potential of TROP2-directed ADC, datopotamab deruxtecan, in this setting.<\/p>\n
PARP inhibitor olaparib is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with Merck & Co., Inc., known as MSD outside the US and Canada, continue to research olaparib in metastatic breast cancer patients with an inherited BRCA mutation and are exploring new opportunities to treat these patients earlier in their disease.<\/p>\n
To bring much-needed treatment options to patients with triple-negative breast cancer, an aggressive form of breast cancer, AstraZeneca is testing immunotherapy durvalumab in combination with other oncology medicines, including olaparib and fam-trastuzumab deruxtecan-nxki, evaluating the potential of capivasertib in combination with chemotherapy, and datopotamab deruxtecan.<\/p>\n
AstraZeneca in oncology<\/p>\n
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.<\/p>\n
The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.<\/p>\n
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.<\/p>\n
About AstraZeneca<\/p>\n
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.<\/p>\n
References<\/p>\n
1 Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 10.3322\/caac.21660.
2 National Cancer Institute. Surveillance, Epidemiology and End Results Program. Available at https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html. Accessed October 2022.
3 Lin M, et al. Comparative Overall Survival of CDK4\/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. J Cancer. 2020; 10.7150\/jca.48944.
4 Bae SY, et al. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 2015; 10.1186\/s12885-015-1121-4.
5 Lumachi F, et al. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem. 2015; 10.4331\/wjbc.v6.i3.231.<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20221026005413\/en\/<\/span><\/p>\n Contacts<\/p>\n Media Inquiries Results reinforce commitment to next-generation oral SERD development program WILMINGTON, Del., October 26, 2022–(BUSINESS WIRE)–Positive high-level results from the SERENA-2 Phase II trial showed that AstraZeneca\u2019s next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant met the primary endpoint of demonstrating a statistically significant and clinically meaningful progression-free survival (PFS) benefit at both 75mg and 150mg […]<\/p>\n","protected":false},"author":1,"featured_media":4115,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[5],"class_list":{"0":"post-4114","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-dolor-de-espalda","8":"tag-dolor-de-espalda"},"_links":{"self":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts\/4114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/comments?post=4114"}],"version-history":[{"count":1,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts\/4114\/revisions"}],"predecessor-version":[{"id":4116,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/posts\/4114\/revisions\/4116"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/media\/4115"}],"wp:attachment":[{"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/media?parent=4114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/categories?post=4114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/americanchiropractors.org\/es\/wp-json\/wp\/v2\/tags?post=4114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Brendan McEvoy +1 302 885 2677
Chelsea Ford +1 302 885 2677
US Media Mailbox: usmediateam@astrazeneca.com<\/p>\n","protected":false},"excerpt":{"rendered":"